Showing results (71-80 of 169) with videos related to

Sort By:
Pageof 17
Investigational New Drugs|February 4, 2010
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimensJaafar Bennouna, Istvan Lang, Manuel Valladares-Ayerbes, et al.
Radiation Oncology (London, England)|September 28, 2011
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survivalLucie Oberic, Frédéric Viret, Charlotte Baey, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2019
Cost-Effectiveness of Web-Based Patient-Reported Outcome Surveillance in Patients With Lung CancerThibaut Lizée, Ethan Basch, Pierre Trémolières, et al.
Cancers|March 13, 2025
Absolute Quantification of Nucleotide Variants in Cell-Free DNA via Quantitative NGS: Clinical Application in Non-Small Cell Lung Cancer PatientsGuillaume Herbreteau, Marie Marcq, Chloé Sauzay, et al.
The Lancet. Oncology|March 3, 2015
Safety and activity of alisertib, an investigational aurora kinase A inhibitor, in patients with breast cancer, small-cell lung cancer, non-small-cell lung cancer, head and neck squamous-cell carcinoma, and gastro-oesophageal adenocarcinoma: a five-arm phase 2 studyBohuslav Melichar, Antoine Adenis, A Craig Lockhart, et al.
ESMO Open|August 11, 2018
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)Jaafar Bennouna, Fabrice Barlesi, Pascal Do, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 25, 2009
Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancerEric Van Cutsem, Walter L Vervenne, Jaafar Bennouna, et al.
British Journal of Cancer|November 24, 2017
Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective studyMaëva Salimon, Caroline Prieux-Klotz, David Tougeron, et al.
Future Oncology (London, England)|May 2, 2024
LEAP-014: first-line lenvatinib + pembrolizumab + chemotherapy in advanced/metastatic esophageal squamous cell carcinomaJong-Mu Sun, Antoine Adenis, Peter C Enzinger, et al.
Cancer Immunology, Immunotherapy : CII|February 28, 2008
Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinomaJaafar Bennouna, Emmanuelle Bompas, Eve Marie Neidhardt, et al.
Pageof 17